# TearExo Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tearexo-co

- Industry: Medical Devices & Equipment
- Headquarters: Kobe, Japan
- Website: www.tearexo.jp
- Total disclosed funding: $0.3M
- Latest round: Seed (Aug 4, 2023)
- Investors on record: 5

## About

Founded in 2022 and based in Japan, TearExo Co., Ltd. operates as a medical equipment firm that offers cancer detection solutions. The company was founded by its CEO, Ryo Horikawa, CTO Eri Takano, CSO Akiko Ichikawa, and Toshifumi Takeuchi. In August 2023, TearExo raised JPY 50 million in seed funding led by Kobe University Capital, Chugin Capital Partners, Future Venture Capital, Japan Startup Support Association, and Leave a Nest Capital.

TearExo offers a medical device that helps users detect cancer, mainly breast cancer, using tears, and increases the detection rate of breast cancer through cancer screening, health examinations, and thorough medical examinations with the help of ultrasonography and ultrasound J-START. The company uses Schirmer test paper to collect tears from homes, send them to a lab for testing, and after doing their study and analysis, they can find cancer without visiting hospitals.

The company plans to use the investment raised in August 2023 to strengthen research and development and expand the coverage of its disease detection method.

## Funding rounds

- Seed, Aug 4, 2023, $0.3M — MIRAIDOOR, Leave a Nest Capital, Japan Startup Support Association, Chugin Capital Partners, Kobe University Capital

## Investors

- MIRAIDOOR (https://capitalatlas.ai/funds/miraidoor) — Seed
- Leave a Nest Capital (https://capitalatlas.ai/funds/leave-a-nest-capital) — Seed
- Japan Startup Support Association (https://capitalatlas.ai/funds/japan-startup-support-association) — Seed
- Chugin Capital Partners (https://capitalatlas.ai/funds/chugin-capital-partners) — Seed
- Kobe University Capital (https://capitalatlas.ai/funds/kobe-university-capital) — Seed